Niekbachsh Mohammadnia

Niekbachsh Mohammadnia

Auto-generated profile, based on publicly available information

Niekbachsh Mohammadnia

Heart and Vascular Institute, Mass General Brigham , 55 Fruit St, Boston, MA 02114

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2023 in Clinical Therapeutics
Verified
Journal Article
Open access
NMN. Mohammadnia
N. Mohammadnia
TOT.S.J. Opstal
T.S.J. Opstal
SMS. El Messaoudi
S. El Messaoudi
WBW.A. Bax
W.A. Bax
JCJ.H. Cornel
J.H. Cornel
This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years. This critical review evaluated how recent publications and ongoing clinical trials in atherosclerotic inflammation will affect clinical care. Key trials, including CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) with canakinumab (interleukin-1β inhibition), and COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low Dose Colchicine 2) with colchicine, have shown that suppressing inflammation can improve outcomes in ASCVD. Cholesterol crystals play an important role in activating the NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome and subsequent cytokine cascade. Inflammation contributes to significant residual risk after optimal lipid-lowering therapy. High-sensitivity C-reactive protein is a recognized biomarker of residual risk, and newer biomarkers such as the neutrophil to lymphocyte ratio may add additional information. The role of lipoprotein(a) as a proinflammatory agent or possible inflammatory biomarker is under investigation. The contribution of clonal hematopoiesis of indeterminate potential and trained immunity are in the early stages of investigation. Ongoing clinical trials of suppressing inflammation with NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome inhibition (colchicine) and alternative approaches with downstream interleukin-6 ligand inhibition (ziltivekimab) will expand the evidence base for the use of anti-inflammatory agents in ASCVD. Based on current evidence and ongoing clinical trials, targeting inflammation alongside optimal lipid lowering is likely to be central to the future treatment of ASCVD. (Clin Ther. 2023;45:XXX-XXX) © 2023 Elsevier HS Journals, Inc.

26 April 2025 in Atherosclerosis
Verified
Journal Article
Open access
NMNiekbachsh Mohammadnia
Niekbachsh Mohammadnia
ABAmber van Broekhoven
Amber van Broekhoven
WBWillem A. Bax
Willem A. Bax
JEJohn W. Eikelboom
John W. Eikelboom
AMArend Mosterd
Arend Mosterd
SMSaloua El Messaoudi
Saloua El Messaoudi
There is a need for effective tools to stratify and modify cardiovascular risk associated with elevated lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPL). The objective of this analysis was to explore the modifying effects of low-grade inflammation on Lp(a)- and OxPL-associated risk in a secondary prevention cohort. Levels of Lp(a), OxPL associated with apolipoprotein(a) (OxPL-apo[a]) and apolipoprotein B (OxPL-apoB) were determined in the placebo-arm of the low-dose colchicine 2 trial. Patients were between 35 and 82 years, had established chronic coronary syndrome (CCS), and were clinically stable for at least six months prior to randomization. The outcome was the incidence of the composite endpoint of spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization stratified by biomarker levels using a Cox regression model. There was a significant interaction between Lp(a) and IL-6 <3.2 ng/L (median) and IL-6 ≥3.2 ng/L for the composite endpoint (HR 0.90; 95 %CI 0.78-1.03 vs HR 1.18; 95 %CI 1.01-1.39, Pinteraction = 0.01). No interaction was found for Lp(a) levels in participants with hsCRP <2 mg/L (HR 1.00; 95 %CI 0.89-1.14) versus those with hsCRP ≥2 mg/L (HR 1.04; 95 %CI 0.86-1.25, Pinteraction = 0.79). In line with Lp(a) levels, significant interaction was observed between OxPL-apo(a) as well as OxPL-apoB levels for the composite endpoint with IL-6 (Pinteraction<0.01 and 0.03, respectively), but not for hsCRP. In patients with CCS, Lp(a), OxPL-apo(a) and OxPL-apoB associated cardiovascular risk was only pertinent in those with elevated IL-6 but not hsCRP levels.

28 March 2026 in European Heart Journal
Verified
Journal Article
Open access
DEDaniel Ezzat
Daniel Ezzat
DLDiana M Lopez
Diana M Lopez
BCBrian L Claggett
Brian L Claggett
LLLinke Li
Linke Li
NMNiekbachsh Mohammadnia
Niekbachsh Mohammadnia
MHMichael C Honigberg
Michael C Honigberg
Background and Aims: Elevated lipoprotein(a) [Lp(a)] levels are an established risk factor for atherosclerotic cardiovascular disease, but the association between Lp(a) and venous thromboembolism (VTE) remains unclear. Sex and hormonal status may modify the relationship between Lp(a) and VTE. Methods: The present study included participants from the UK Biobank with available baseline Lp(a) data. Individuals with a history of VTE or cancer, as well as those using anticoagulants, were excluded. Multivariable-adjusted Cox models were used to assess the association between Lp(a) levels ≥125 nmol/L and incident VTE in premenopausal women, postmenopausal women, and men. Subgroup analyses stratified premenopausal women by oral contraceptive (OCP) use and postmenopausal women by menopausal hormone therapy (MHT) use. Results: Among 55 302 premenopausal women, 129 045 postmenopausal women, and 189 013 men, the proportions with Lp(a) ≥ 125 nmol/L were 14.0%, 19.0%, and 15.0%, respectively. Over a median (interquartile range) follow-up of 13.6 (12.9–14.4) years, 8186 VTE events occurred (cumulative incidence 2.2%). Lp(a) ≥ 125 nmol/L was associated with incident VTE in premenopausal women [adjusted hazard ratio (aHR) 1.32; 95% confidence interval (CI) 1.04–1.66; P = .02] but not in postmenopausal women (aHR 1.03; 95% CI 0.94–1.13; P = .47; Pinteraction = .03) or men (aHR 1.00; 95% CI 0.92–1.08; P = .94). OCP use did not modify the Lp(a)-VTE association among premenopausal women (Pinteraction = .61). However, among postmenopausal MHT users, Lp(a) ≥ 125 nmol/L was associated with higher VTE risk (aHR 1.48; 95% CI 1.03–2.12; P = .03; Pinteraction = .04). Conclusions: Elevated Lp(a) was associated with VTE in premenopausal women and in postmenopausal MHT users, suggesting that hormonal context may influence Lp(a)-associated thrombotic risk.

15 July 2025 in American Heart Journal
Verified
Journal Article
Open access
NMNiekbachsh Mohammadnia
Niekbachsh Mohammadnia
LVLucas T.W. Vestjens
Lucas T.W. Vestjens
NCNeil J. Craig
Neil J. Craig
JTJan G.P. Tijssen
Jan G.P. Tijssen
RKRemco J.J. Knol
Remco J.J. Knol
SMSaloua El Messaoudi
Saloua El Messaoudi
Aortic valve stenosis (AS) is one of the most common valvular heart diseases worldwide. Its prevalence increases with age and is expected to rise further as the population ages. Untreated severe AS carries a 2-year mortality rate exceeding 50%. Furthermore, surveillance and management of AS impose a significant burden on healthcare systems. Therefore, effective pharmacological strategies are urgently needed to slow or halt the progression of AS. Inflammation plays a central role in the pathogenesis of both atherosclerosis and AS. Anti-inflammatory therapy with low-dose colchicine reduces cardiovascular events in patients with coronary artery disease, but its efficacy has not been tested in AS. Colchicine and Inflammation in Aortic Stenosis (CHIANTI) is an investigator-initiated, placebo-controlled, double-blind, multicenter, randomized trial involving 150 patients with moderate AS. After confirming tolerance during a two-week run-in phase, eligible participants underwent coronary computed tomography (CT) angiography, 18F-sodium fluoride (18F-NaF) positron emission tomography (PET)-CT, and echocardiography. Thereafter, participants were randomized 1:1 to colchicine 0.5 mg once daily or a matching placebo. All baseline imaging is repeated after 24 months. The primary endpoint is the change in aortic valve calcium score on CT. Secondary endpoints are (1) the change in aortic valve 18F-NaF uptake on PET-CT and corrected for target-to-background ratio, and (2) the change in peak aortic jet velocity on echocardiography. The CHIANTI trial evaluates whether anti-inflammatory therapy with low-dose colchicine can slow or halt the progression of moderate AS. If successful, it would offer the first effective pharmacological treatment for AS. Registered on ClinicalTrials.gov (https://clinicaltrials.gov/), ID: NCT05162742.

21 March 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
NMNiekbachsh Mohammadnia
Niekbachsh Mohammadnia
CKCornelis Kramers
Cornelis Kramers
ACAysun Cetinyurek-Yavuz
Aysun Cetinyurek-Yavuz
SMSaloua El Messaoudi
Saloua El Messaoudi

9 February 2026 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
ACAnnie Chang
Annie Chang
NMNiekbachsh Mohammadnia
Niekbachsh Mohammadnia
MHMichael C Honigberg
Michael C Honigberg